One of the UK’s leading development stage pharmaceutical companies, Vernalis takes promising product candidates along a commercially-focused path to market. We derive pipeline candidates both from successful collaborations with a number of global pharmaceutical businesses and our own research activities. Our pipeline reflects our strategy and is split between our later stage commercial pipeline and our NCE portfolio.

 The strategy is to:

  • Build a profitable and cash generative business
  • Develop and commercialise low-risk late stage products for unmet medical need
  • Partner all of our drug candidates; selective investment in our in-house products


See where Vernalis is now

View the pipeline, plus our staffing and research capabilities

Get an Overview

Experienced, successful, engaged leadership

For a company this size, our directors and senior management stand out

Meet Our People


Interested in working with us?

Check out current vacancies and see the specialisations we are looking for

Careers at Vernalis

Clear direction for the competitive biotech sector

What therapeutic areas are we targeting, and what strategies do we rely on to achieve results?

Vision and strategy

Where does Vernalis come from?

The history of the organisation, and the relationships we’ve developed

A little History

We take our responsibilities seriously

Good governance and good practice are inherent in all our operations

Corporate Social Responsibility

Latest News

Moxatag Supply Update

Vernalis plc ("Vernalis" or the "Company") was informed yesterday that Suir Pharma Limited ("Suir") of Clonmel Ireland, the sole source supplier of finished dosage form Moxatag®, has been placed into Provisional Liquidation.

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form